1. Pink Sheet
  2. >>Market Access

Count Me In! China To Update Drug Coverage After Long Wait

 
• By Brian Yang

After a long seven-year hiatus, China is finally moving to update its national reimbursement drug list, but the process will involve huge numbers of experts and the benefits of inclusion may not be as immediate or as extensive as appear at first sight.

China globe

Just a day before the major National Day holiday period began on Oct. 1, China's Ministry of Human Resources and Social Security (MHRSS) on Sept.30 released for public comment a long-awaited new draft of proposals for the revision of the National Reimbursement Drug List (NRDL).

The five-page document, which is meant to outline some guiding principles of the selection process, could also benefit drug makers...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.